Hikma Pharmaceuticals no longer appears to be challenging the validity of Pfizer’s patent

Written By yadhziwikwknxz

Update from the Vyndamax (tafamidis) trial: Hikma Pharmaceuticals, the holdout defendant, no longer appears to be challenging the validity of Pfizer’s patent.

Two of three defendants have settled, and now the final defendant is relying on its product not infringing Pfizer’s patent.

Positive signs for $PFE $BBIO $ALNY, bearish for $HIK.

yadhziwikwknxz
Previous

Catalyst Pharmaceuticals draws Italian buyer interest as US rare disease assets fetch premium
Next

Novartis wins EU green light for Rhapsido in chronic urticaria, opening front in oral immunology drugs